Enhanced Immunological Protection Against Toxic Agents via Transection of Rearranged Immunoglobulin Genes into Hematopoietic Stem Cells
Annual rept. 1989-1990
NAVAL MEDICAL RESEARCH AND DEVELOPMENT COMMAND BETHESDA MD
Pagination or Media Count:
The primary effort of the research has been directed at the development of anti-idiotypic anti-id antibodies against the myeloma protein MOPC-167 M167. We have developed anti-id antibodies against this phosphocholine PC binding myeloma protein because we will be using the rearranged variable region genes VH167 Vk167 from this myeloma cell line, ligated to germ-line mu kappa constant region genes, for transfection into both mouse and human stem cells. Once these genes have been successfully transfected into stem cells and these cells transplanted into SCID mice, one must have anti-id reagents to 1 follow the development of the cells expressing the transfected gene products and, 2 activate the B cells expressing the M167 antibody as an antigen-specific receptor on their cell surface. This model system is to serve as a prototype for testing the feasibility of transfecting stem cells with antibody genes whose product is directed against an agent pathogenic or chemical which cannot be safely used as an immunogen.